Vident Investment Advisory’s Ionis Pharmaceuticals IONS Stock Holding History

Vident Investment Advisory’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,587	Closed	-$223K	–	1196
2021 Q2	$223K	Buy	+5,587	New	+$219K	0.01%	1010
2020 Q3	–	Sell	-8,033	Closed	-$474K	–	902
2020 Q2	$474K	Buy	+8,033	New	+$447K	0.02%	663
2018 Q4	–	Sell	-4,110	Closed	-$212K	–	837
2018 Q3	$212K	Sell	4,110 -1,732	-30%	-$81.4K	0.01%	896
2018 Q2	$243K	Buy	5,842 +65	+1%	+$2.88K	0.01%	837
2018 Q1	$252K	Buy	5,777 +130	+2%	+$6.6K	0.01%	812
2017 Q4	$284K	Sell	5,647 -201	-3%	-$11K	0.01%	704
2017 Q3	$296K	Buy	+5,848	New	+$306K	0.02%	628

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vident Investment Advisory's IONS Position: Q3 2021 in Review

Vident Investment Advisory sold out of Ionis Pharmaceuticals (IONS) in Q3 2021, closing a stake of 5,587 shares — an estimated $223K sold.

Vident Investment Advisory first reported a position in IONS in Q3 2017 and held it in 7 quarters. The position peaked at $474K in Q2 2020. 324 funds tracked by Wall St. Rank hold IONS as of Q3 2021.

Vident Investment Advisory reported no remaining Ionis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Vident Investment Advisory sold 5,587 Ionis Pharmaceuticals shares in Q3 2021, an estimated $223K.
Vident Investment Advisory first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 7 quarters.
Vident Investment Advisory's Ionis Pharmaceuticals position peaked at $474K in Q2 2020.
324 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.